{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:42:55Z","timestamp":1794084175557,"version":"4.8.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Outcomes in older adults with classic Hodgkin lymphoma (cHL) have traditionally been poor, in part, related to poor tolerance to standard chemotherapy. Herein, we evaluated the survival of patients with cHL aged \u226560 years in British Columbia in a population-based analysis. From 1961 to 2019, 744 patients with newly diagnosed cHL were identified. With a median follow-up of 9 years, 5-year disease-specific survival (DSS) and overall survival (OS) have improved by decade comparison (both P\u00a0&amp;lt; .001), remaining stable in the past 20 years (DSS, P\u00a0= .35; OS, P\u00a0= .26). In the modern management era (2000-present), 361 of 401 patients (90%) received active therapy for cHL and had a 5-year OS of 60%. For those who received curative-intent therapy (n\u00a0= 327), the 5-year progression-free survival (PFS), OS, and DSS were 60%, 65%, and 76%, respectively, and estimates were superior in those who were 60 to 69\u00a0years of age (72%, 77%, and 83%, respectively) compared with those who were 70 to 79\u00a0years of age (54%, 57%, and 70%, respectively) and \u226580 years of age (28%, 39%, and 63%, respectively) (P\u00a0&amp;lt; .05 for all). Overall, pulmonary toxicity occurred in 58 of 279 patients (21%) treated with bleomycin, with 22 of 58 (38%) occurring after cycles 1 or 2, accounting for 8 of 20 (40%) treatment-related deaths. Outcomes in older adults with cHL have improved in recent decades; however, they remain poor for those aged \u226570 years, even in the modern treatment era. Furthermore, treatment-related toxicity remains a significant concern and use of bleomycin should be avoided in most patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008258","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T16:04:01Z","timestamp":1662653041000},"page":"5924-5932","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["The outcome of older adults with classic Hodgkin lymphoma in British Columbia"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-8608","authenticated-orcid":false,"given":"Phoebe T. M.","family":"Cheng","sequence":"first","affiliation":[{"name":"1Centre for Lymphoid Cancer and Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer and Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1425","authenticated-orcid":false,"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer and Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"2H Lee Moffitt Cancer Centre & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham W.","family":"Slack","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer and Department of Pathology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer and Department of Pathology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-9391","authenticated-orcid":false,"given":"Pedro","family":"Farinha","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer and Department of Pathology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-3258","authenticated-orcid":false,"given":"Jeffrey W.","family":"Craig","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer and Department of Pathology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Skinnider","sequence":"additional","affiliation":[{"name":"3Centre for Lymphoid Cancer and Department of Pathology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Wilson","sequence":"additional","affiliation":[{"name":"4Division of Radiology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer and Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-7531","authenticated-orcid":false,"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer and Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer and Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer and Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2022112216255455200_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11864-020-00745-9","article-title":"Current treatment options for older patients with Hodgkin lymphoma","volume":"21","author":"Carter","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"22","key":"2022112216255455200_bib2","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"S1","key":"2022112216255455200_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2070","article-title":"XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes","volume":"31","author":"Jagadeesh","year":"2013","journal-title":"Hematol Oncol"},{"issue":"30","key":"2022112216255455200_bib4","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1200\/JCO.2005.02.6310","article-title":"Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study","volume":"23","author":"Keegan","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2022112216255455200_bib5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Hodgkin\u2019s disease in the elderly: a population-based study","volume":"119","author":"Stark","year":"2002","journal-title":"Br J Haematol"},{"issue":"3","key":"2022112216255455200_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2141.2004.04902.x","article-title":"Epstein-Barr virus-associated Hodgkin's lymphoma","volume":"125","author":"Gandhi","year":"2004","journal-title":"Br J Haematol"},{"issue":"7","key":"2022112216255455200_bib7","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1182\/blood-2004-09-3759","article-title":"Scotland and Newcastle Epidemiology of Hodgkin Disease Study Group. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study","volume":"106","author":"Jarrett","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2022112216255455200_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3109\/10428194.2015.1086919","article-title":"Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with Hodgkin lymphoma","volume":"57","author":"Brooks","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2022112216255455200_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"17","key":"2022112216255455200_bib10","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2022112216255455200_bib11","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2022112216255455200_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2022112216255455200_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"issue":"26","key":"2022112216255455200_bib14","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2017-10-812966","article-title":"Initial Hodgkin treatment of the frail elderly","volume":"130","author":"Straus","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2022112216255455200_bib15","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"issue":"5","key":"2022112216255455200_bib16","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"102","author":"Evens","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"2022112216255455200_bib17","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.3324\/haematol.2018.196782","article-title":"Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD","volume":"10","author":"Villa","year":"2018","journal-title":"Haematologica"},{"issue":"23","key":"2022112216255455200_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.V126.23.579.579","article-title":"Advanced stage classical Hodgkin lymphoma patients with a negative PET-scan following treatment with ABVD have excellent outcomes without the need for consolidative radiotherapy regardless of disease bulk at presentation","volume":"126","author":"Savage","year":"2015","journal-title":"Blood"},{"issue":"25","key":"2022112216255455200_bib19","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2022112216255455200_bib20","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/annonc\/mdv359","article-title":"Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohort","volume":"26","author":"Bishton","year":"2015","journal-title":"Ann Oncol"},{"key":"2022112216255455200_bib21","doi-asserted-by":"crossref","first-page":"106311","DOI":"10.1016\/j.leukres.2020.106311","article-title":"Czech Hodgkin\u2019s Lymphoma Study Group. Outcome of elderly patients with classical Hodgkin\u2019s lymphoma","volume":"90","author":"Sykorova","year":"2020","journal-title":"Leuk Res"},{"issue":"18","key":"2022112216255455200_bib22","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/bloodadvances.2021004645","article-title":"Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma","volume":"5","author":"Orellana-Noia","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2022112216255455200_bib23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A\u00a0retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"issue":"30","key":"2022112216255455200_bib24","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2022112216255455200_bib25","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll","year":"2016","journal-title":"Blood"},{"issue":"18","key":"2022112216255455200_bib26","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2022112216255455200_bib27","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3109\/10428194.2013.876496","article-title":"Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy","volume":"55","author":"Gopal","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2022112216255455200_bib28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"30","key":"2022112216255455200_bib29","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2022112216255455200_bib30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2022112216255455200_bib31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"KEYNOTE-204 investigators. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study [published correction appears in Lancet Oncol. 2021;22(5):e184.]","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"2022112216255455200_bib32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"issue":"14","key":"2022112216255455200_bib33","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial [published correction appears in J Clin Oncol. 2018;36(26):2748.]","volume":"36","author":"Armand","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2022112216255455200_bib34","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2022112216255455200_bib35","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol"},{"issue":"suppl 15","key":"2022112216255455200_bib36","article-title":"Brentuximab vedotin-mediated immunogenic cell death. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR","volume":"75","author":"Gardai","year":"2015","journal-title":"Cancer Res"},{"issue":"11","key":"2022112216255455200_bib37","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2022112216255455200_bib38","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"},{"issue":"23","key":"2022112216255455200_bib39","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/22\/5924\/2007214\/blooda_adv-2022-008258-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/22\/5924\/2007214\/blooda_adv-2022-008258-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T11:26:24Z","timestamp":1669116384000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/22\/5924\/486555\/The-outcome-of-older-adults-with-classic-Hodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":39,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,11,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008258","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}